CRISPR Therapeutics (CRSP) director receives stock options for 13,000 shares

Rhea-AI Filing Summary

CRISPR Therapeutics AG director Maria Fardis received a grant of stock options, giving her the right to buy 13,000 common shares at an exercise price of $51.84 per share. These options were awarded as compensation, not through open-market buying or selling.

According to the vesting terms, the 13,000 options will vest in 12 equal monthly installments, with the first installment vesting on June 30, 2026. The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the company’s 2027 Annual Meeting, assuming she continues to provide service to the company or its subsidiaries.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fardis Maria

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 13,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 13,000 options Exercise price: $51.84 per share Underlying shares: 13,000 common shares +3 more

6 metrics

Options granted 13,000 options Stock Option (Right to Buy) granted to Maria Fardis

Exercise price <money>$51.84</money> per share Conversion or exercise price of granted options

Underlying shares 13,000 common shares Underlying security for the option grant

Total derivative holdings after grant 13,000 options Total shares following transaction for this option award

Option expiration <date>June 5, 2036</date> Expiration date of the granted stock options

Vesting start date <date>June 30, 2026</date> First of 12 equal monthly vesting installments

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Annual Meeting

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion or exercise price of 51.8400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"the options will vest and become exercisable in 12 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting financial

"the last installment vests on the earlier of one year anniversary or the 2027 Annual Meeting"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fardis Maria

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$51.84	06/05/2026		A		13,000		(1)	06/05/2036	Common Shares	13,000	$0	13,000	D

Explanation of Responses:

1. Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

	/s/ Elizabeth Ryland Waldinger	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CRISPR Therapeutics (CRSP) report for Maria Fardis?

CRISPR Therapeutics reported that director Maria Fardis received a grant of stock options for 13,000 common shares. These are compensation-related options, not open-market purchases or sales, and give her the right to buy shares at a fixed exercise price.

How many CRISPR Therapeutics (CRSP) shares are covered by Maria Fardis’s new options?

Maria Fardis’s new stock option grant covers 13,000 underlying common shares. Each option represents the right to purchase one share, subject to vesting and an exercise price, aligning her compensation with CRISPR Therapeutics’ long-term share performance.

What is the exercise price of Maria Fardis’s CRISPR Therapeutics (CRSP) stock options?

The exercise price of Maria Fardis’s stock options is $51.84 per share. This means she can buy CRISPR Therapeutics common shares at that fixed price once the options vest and she chooses to exercise them, assuming she continues her service.

When do Maria Fardis’s CRISPR Therapeutics (CRSP) options vest?

The 13,000 stock options vest in 12 equal monthly installments, starting with the first installment on June 30, 2026. The final installment vests on the earlier of the one-year grant anniversary or the date of the 2027 Annual Meeting, subject to continued service.

Is Maria Fardis’s CRISPR Therapeutics (CRSP) Form 4 transaction a market purchase or sale?

The Form 4 transaction is not a market purchase or sale. It reflects a compensation-related grant of stock options coded as a grant or award, giving Maria Fardis rights to acquire shares in the future at a set exercise price.